TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+1.29%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$330M
AUM Growth
+$330M
(+69%)
Cap. Flow
+$134M
Cap. Flow
% of AUM
40.67%
Top 10 Holdings %
Top 10 Hldgs %
74.15%
Holding
31
New
9
Increased
11
Reduced
2
Closed
8
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$29.2M |
| 2 |
VRNA
Verona Pharma
VRNA
|
$20.5M |
| 3 |
Ascendis Pharma
ASND
|
$19.9M |
| 4 |
UnitedHealth
UNH
|
$18.9M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$18.1M |
Top Sells
| 1 |
Cigna
CI
|
$24.3M |
| 2 |
McKesson
MCK
|
$18.1M |
| 3 |
Gilead Sciences
GILD
|
$10M |
| 4 |
Illumina
ILMN
|
$9.58M |
| 5 |
Insmed
INSM
|
$7.77M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceuticals
TEVA
$21.1B
| $34.3M | 10.41% | 2,046,846 +985,838 | +93% | +$16.5M |
|
|
2
Madrigal Pharmaceuticals
MDGL
$9.76B
| $29.6M | 8.98% | 97,765 +59,896 | +158% | +$18.1M |
|
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $29.2M | 8.86% | +89,525 | New | +$29.2M |
|
4
argenx
ARGX
$43.6B
| $26.3M | 8% | 47,793 +29,949 | +168% | +$16.5M |
|
|
5
Ascendis Pharma
ASND
$11.8B
| $25.5M | 7.73% | 147,642 +115,317 | +357% | +$19.9M |
|
6
Soleno Therapeutics
SLNO
$3.6B
| $24.2M | 7.34% | 288,880 +53,960 | +23% | +$4.52M |
|
|
VRNA
7
Verona Pharma
VRNA
$9.16B
| $20.5M | 6.22% | +216,578 | New | +$20.5M |
|
8
Inspire Medical Systems
INSP
$2.77B
| $19.4M | 5.88% | 149,244 +70,432 | +89% | +$9.14M |
|
|
9
UnitedHealth
UNH
$281B
| $18.9M | 5.74% | +60,584 | New | +$18.9M |
|
10
Axsome Therapeutics
AXSM
$6.05B
| $16.5M | 5% | 157,861 +56,621 | +56% | +$5.91M |
|
11
Evolus
EOLS
$494M
| $11.4M | 3.46% | 1,239,031 +917,229 | +285% | +$8.45M |
|
12
AbbVie
ABBV
$372B
| $10.3M | 3.14% | +55,661 | New | +$10.3M |
|
13
Vera Therapeutics
VERA
$1.38B
| $9.73M | 2.95% | 413,114 +262,907 | +175% | +$6.19M |
|
|
AVDL
14
Avadel Pharmaceuticals
AVDL
$1.43B
| $8.98M | 2.72% | +1,014,456 | New | +$8.98M |
|
15
Praxis Precision Medicines
PRAX
$958M
| $8.22M | 2.49% | 195,432 +111,773 | +134% | +$4.7M |
|
16
Tarsus Pharmaceuticals
TARS
$2.47B
| $7.2M | 2.18% | +177,656 | New | +$7.2M |
|
17
Intuitive Surgical
ISRG
$170B
| $6.97M | 2.11% | +12,824 | New | +$6.97M |
|
18
Legend Biotech
LEGN
$6.41B
| $6.15M | 1.87% | +173,260 | New | +$6.15M |
|
19
Nuvalent
NUVL
$5.52B
| $5.8M | 1.76% | 75,973 -19,852 | -21% | -$1.51M |
|
20
Biohaven
BHVN
$1.63B
| $3.83M | 1.16% | +271,367 | New | +$3.83M |
|
21
Korro Bio
KRRO
$217M
| $3.48M | 1.06% | 139,493 +11,112 | +9% | +$278K |
|
22
GeneDx Holdings
WGS
$3.72B
| $3.04M | 0.92% | 32,931 -25,214 | -43% | -$2.33M |
|
23
Femasys
FEMY
$11.6M
| $29.6K | 0.01% | 30,606 | – | – |
|
|
BPMC
24
DELISTED
Blueprint Medicines
BPMC
| – | – | -50,000 | Closed | -$4.43M |
|
|
25
Cigna
CI
$80.3B
| – | – | -73,905 | Closed | -$24.3M |
|